Standard BioTools Statistics
Total Valuation
LAB has a market cap or net worth of $249.68 million. The enterprise value is -$184.60 million.
| Market Cap | 249.68M |
| Enterprise Value | -184.60M |
Important Dates
The next estimated earnings date is Friday, November 20, 2026, after market close.
| Earnings Date | Nov 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LAB has 392.58 million shares outstanding. The number of shares has increased by 2.75% in one year.
| Current Share Class | 392.58M |
| Shares Outstanding | 392.58M |
| Shares Change (YoY) | +2.75% |
| Shares Change (QoQ) | +0.68% |
| Owned by Insiders (%) | 1.83% |
| Owned by Institutions (%) | 24.35% |
| Float | 185.63M |
Valuation Ratios
The trailing PE ratio is 1.86.
| PE Ratio | 1.86 |
| Forward PE | n/a |
| PS Ratio | 2.96 |
| Forward PS | 3.04 |
| PB Ratio | 0.45 |
| P/TBV Ratio | 0.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.75, with a Debt / Equity ratio of 0.05.
| Current Ratio | 9.75 |
| Quick Ratio | 9.29 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,953.88 |
Financial Efficiency
Return on equity (ROE) is -7.79% and return on invested capital (ROIC) is -5.85%.
| Return on Equity (ROE) | -7.79% |
| Return on Assets (ROA) | -5.03% |
| Return on Invested Capital (ROIC) | -5.85% |
| Return on Capital Employed (ROCE) | -8.09% |
| Weighted Average Cost of Capital (WACC) | 11.33% |
| Revenue Per Employee | $217,044 |
| Profits Per Employee | $342,098 |
| Employee Count | 389 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 1.88 |
Taxes
| Income Tax | -35.80M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.21% in the last 52 weeks. The beta is 1.51, so LAB's price volatility has been higher than the market average.
| Beta (5Y) | 1.51 |
| 52-Week Price Change | -44.21% |
| 50-Day Moving Average | 0.68 |
| 200-Day Moving Average | 0.89 |
| Relative Strength Index (RSI) | 47.05 |
| Average Volume (20 Days) | 826,076 |
Short Selling Information
The latest short interest is 2.45 million, so 0.62% of the outstanding shares have been sold short.
| Short Interest | 2.45M |
| Short Previous Month | 2.52M |
| Short % of Shares Out | 0.62% |
| Short % of Float | 1.32% |
| Short Ratio (days to cover) | 2.55 |
Income Statement
In the last 12 months, LAB had revenue of $84.43 million and earned $133.08 million in profits. Earnings per share was $0.34.
| Revenue | 84.43M |
| Gross Profit | 44.05M |
| Operating Income | -47.26M |
| Pretax Income | -73.03M |
| Net Income | 133.08M |
| EBITDA | -38.09M |
| EBIT | -47.26M |
| Earnings Per Share (EPS) | $0.34 |
Balance Sheet
The company has $461.11 million in cash and $26.83 million in debt, with a net cash position of $434.28 million or $1.11 per share.
| Cash & Cash Equivalents | 461.11M |
| Total Debt | 26.83M |
| Net Cash | 434.28M |
| Net Cash Per Share | $1.11 |
| Equity (Book Value) | 555.75M |
| Book Value Per Share | 1.41 |
| Working Capital | 446.28M |
Cash Flow
In the last 12 months, operating cash flow was -$64.26 million and capital expenditures -$1.39 million, giving a free cash flow of -$65.65 million.
| Operating Cash Flow | -64.26M |
| Capital Expenditures | -1.39M |
| Depreciation & Amortization | 9.17M |
| Net Borrowing | n/a |
| Free Cash Flow | -65.65M |
| FCF Per Share | -$0.17 |
Margins
Gross margin is 52.18%, with operating and profit margins of -55.98% and 157.62%.
| Gross Margin | 52.18% |
| Operating Margin | -55.98% |
| Pretax Margin | -86.50% |
| Profit Margin | 157.62% |
| EBITDA Margin | -45.12% |
| EBIT Margin | -55.98% |
| FCF Margin | n/a |
Dividends & Yields
LAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.75% |
| Shareholder Yield | -2.75% |
| Earnings Yield | 53.73% |
| FCF Yield | -26.29% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 0.14% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |